摘要
目的分析三种用于2型糖尿病（T2DM）治疗方案的效果与成本的关系，以得出最合理的治疗方案。方法利用药物经济学原理，回顾性分析198例T2DM患者的病例资料，对格列美脲、瑞格列奈、罗格列酮三种用于T2DM的药物进行药物成本-效果分析。结果三种方案的总有效率没有显著差异，而三种方案的成本．效果比（C／E）分别为：2．99、1．43、5．76，三种方案的增量成本．效果比（AC／AE）分别为：42．15、18．32、214．74。结论应根据患者的个体差异，选择治疗效果最好，价格最低，安全系数最高的治疗方案。
Objective To analyze the cost-effectiveness of the treatment of type 2 diabetes by 3 different drugs. Methods Through the retrospective analysis of 198 cases with T2DM and drug economlcs,to analyze the costeffectiveness of the Yamo Li（ glimepiride）, repaglinide（repaglinide） and Avandia（ rosiglitazone）. Results No significant difference was observed in the total effective rate among the 3 drugs. The cost-effectiveness ratios in Group A, B and C were 2.99,1.43 and 5.76. The cost-effectiveness ratios increments in Group A,B and C were 42. 15,18.32 and 214.74. Conclusion Based on individual differences of the patients, doctor should choose the drug with best treatment, lowest price and highest safety.
出处
《中国基层医药》
CAS
2012年第3期355-356,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
糖尿病
2型
临床方案
费用
药物
Diabetes mellitus, type 2
Clinical protocols
Fees ,pharmaceutical
